Premium
The case against laetrile. The fraudulent cancer remedy
Author(s) -
Greenberg David M.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800215)45:4<799::aid-cncr2820450432>3.0.co;2-6
Subject(s) - amygdalin , medicine , cancer , rhodanese , traditional medicine , pharmacology , biochemistry , enzyme , pathology , biology , alternative medicine
The evidence for the claims that laetrile (amygdalin) can prevent or control cancers has been reviewed. The β‐glucosidase content of cancer tissues is low compared to that of normal liver and small intestine. Cancer tissues contain the enzyme rhodanese in amounts comparable to that of liver and kidney and hence, cannot be attacked selectively by cyanide release through β‐glucosidase action on amygdalin. Amygdalin does not have the properties of a vitamin. Rats have been reared for several generations on diets devoid of cyanogenic glycosides, without developing neoplasms. Experiments with tumor‐bearing rodents have demonstrated no curative properties by amygdalin administration. Amygdalin is not as non‐toxic as claimed, particularly when ingested orally, and especially when taken with plant material high in β‐glucosidase. The claims for cure and control of cancers in humans have been refuted by distinguished physicians who specialize in the treatment of cancer patients. The writings of laetrile proponents are filled with erroneous and absurd statements. The propaganda for the doctrine of “freedom of choice in cancer treatment” deludes many individuals with treatable cancer to reject proven methods of treatment. Cancer 45:799‐807, 1980.